Teva plans sale of 25,578 ordinary shares

Teva Pharmaceutical Industries Limited has a holder planning to sell ordinary shares under a resale notice.

Accepted by SEC EDGAR 08/03/2026 - 04:01 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Limited has a holder planning to sell ordinary shares under a resale notice. The plan covers 25,578 ordinary shares to be sold through Citigroup Global Markets, Inc. on or after August 3, 2026, with an indicated aggregate market value of $892,050.65. The shares relate to a Restricted Share Unit Award that vested on August 1, 2022 in respect of services rendered.

Key Figures

Shares planned for sale: 25,578 ordinary shares Aggregate market value: $892,050.65 Security identifier: 1165296084 +3 more

6 metrics

Shares planned for sale 25,578 ordinary shares Ordinary shares to be sold through Citigroup Global Markets, Inc. on or after August 3, 2026

Aggregate market value $892,050.65 Value associated with 25,578 ordinary shares planned for sale

Security identifier 1165296084 Identifier listed for Teva Pharmaceutical ordinary shares

Proposed sale date 08/03/2026 Date from which the ordinary shares may be sold on the NYSE

RSU vesting shares 52,744 ordinary shares Restricted Share Unit Award vesting on August 1, 2022 for services rendered

RSU vesting date 08/01/2022 Date of Restricted Share Unit Award vesting related to the shares

Key Terms

Restricted Share Unit Award, ordinary shares, services rendered

3 terms

Restricted Share Unit Award financial

"Ordinary Shares | 08/01/2022 | Restricted Share Unit Award Vesting"

ordinary shares financial

"Ordinary Shares | Citigroup Global Markets, Inc 390 Greenwich St"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

services rendered financial

"52744 | 08/03/2026 | Services Rendered"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What share sale is disclosed for TEVA in this Form 144-type notice?

A holder of Teva Pharmaceutical Industries Limited (TEVA) plans to sell 25,578 ordinary shares through Citigroup Global Markets, Inc. The shares are expected to be sold on or after August 3, 2026 on the NYSE.

What is the approximate value of TEVA shares planned for sale?

The planned sale covers ordinary shares with an aggregate market value of about $892,050.65. This value is tied to the 25,578 shares indicated in the notice for potential sale on or after August 3, 2026.

What is the origin of the TEVA shares being sold under this notice?

The ordinary shares relate to a Restricted Share Unit Award that vested on August 1, 2022. The filing describes the underlying transaction as an RSU vesting in connection with services rendered to Teva Pharmaceutical Industries Limited (TEVA).

Which broker is handling the planned TEVA share sale?

The planned sale of 25,578 TEVA ordinary shares is listed through Citigroup Global Markets, Inc., located at 390 Greenwich St, New York, NY 10013. The sale is expected to occur on the NYSE after the stated date.

Does the filing indicate any recent TEVA equity activity related to this sale?

Yes. It notes a Restricted Share Unit Award vesting on August 1, 2022 for 52,744 ordinary shares. These vested RSUs form the equity source connected to the planned sale associated with services rendered.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001938678
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LTD
SEC File Number	001-16174
Address of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV ISRAEL 6944020
Phone	972 (3) 914-8213
Name of Person for Whose Account the Securities are To Be Sold	Hughes Eric A
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Executive VP Global R&D and Chief Med Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary Shares	Citigroup Global Markets, Inc 390 Greenwich St New York NY 10013	25578	892050.65	1165296084	08/03/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares	08/01/2022	Restricted Share Unit Award Vesting	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			52744	08/03/2026	Services Rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	shares sold were pursuant to a sell to cover transaction from an established 10b51 plan adopted November 2025
Date of Notice	08/03/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/10/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)